LEP and obesity due to melanocortin 4 receptor deficiency: When discussing the potential of leptin-based pharmacotherapy for overweight and obesity it is important to consider that the inconsistent data were often driven by differences in populations studied, the study design and the regimen of the therapy, including dosing, the pharmacological structure of leptin and the trials’ inclusion criteria.